Literature DB >> 22128168

Dissection of Wnt5a-Ror2 signaling leading to matrix metalloproteinase (MMP-13) expression.

Kaoru Yamagata1, Xin Li, Shunkichi Ikegaki, Chitose Oneyama, Masato Okada, Michiru Nishita, Yasuhiro Minami.   

Abstract

It has been shown that constitutively active Wnt5a-Ror2 signaling in osteosarcoma cell lines plays crucial roles in induced expression of matrix metalloproteinase-13 (MMP-13), required for their invasiveness; however, it remains largely unclear about the molecular basis of MMP-13 gene induction by Wnt5a-Ror2 signaling. Here we show by reporter assay that the activator protein 1 (AP1) (binding site in the promoter region of MMP-13 gene is primarily responsible for its transcriptional activation by Wnt5a-Ror2 signaling in osteosarcoma cell lines SaOS-2 and U2OS. Chromatin immunoprecipitation assays revealed that c-Jun and ATF2 are crucial transcription factors recruited to the AP1-binding site in the MMP-13 gene promoter during Wnt5a-Ror2 signaling in SaOS-2 cells. Using siRNA-mediated suppression or specific inhibitors, we also show that Dishevelled2 (Dvl2) and c-Jun N-terminal kinase are required for MMP-13 gene induction presumably via phosphorylation of c-Jun and ATF2 during Wnt5a-Ror2 signaling in SaOS-2 cells. Interestingly, Dvl2 and Rac1, but not Dvl3, are required for MMP-13 expression in SaOS-2 cells, whereas Dvl3, but not Dvl2 and Rac1, is required for its expression in U2OS cells, indicating the presence of distinct intracellular signaling machineries leading to expression of the same gene, in this case MMP-13 gene in different osteosarcoma cell lines. Moreover, we provide evidence suggesting that Wnt5a-Ror2 signaling might also be required for expression of MMP-13 gene during the development of the cartilaginous tissue.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22128168      PMCID: PMC3256912          DOI: 10.1074/jbc.M111.315127

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  Cthrc1 selectively activates the planar cell polarity pathway of Wnt signaling by stabilizing the Wnt-receptor complex.

Authors:  Shinji Yamamoto; Osamu Nishimura; Kazuyo Misaki; Michiru Nishita; Yasuhiro Minami; Shigenobu Yonemura; Hiroshi Tarui; Hiroshi Sasaki
Journal:  Dev Cell       Date:  2008-07       Impact factor: 12.270

2.  Receptor tyrosine kinase Ror2 mediates Wnt5a-induced polarized cell migration by activating c-Jun N-terminal kinase via actin-binding protein filamin A.

Authors:  Akira Nomachi; Michiru Nishita; Daisuke Inaba; Masahiro Enomoto; Mayumi Hamasaki; Yasuhiro Minami
Journal:  J Biol Chem       Date:  2008-07-30       Impact factor: 5.157

3.  Autonomous regulation of osteosarcoma cell invasiveness by Wnt5a/Ror2 signaling.

Authors:  M Enomoto; S Hayakawa; S Itsukushima; D Y Ren; M Matsuo; K Tamada; C Oneyama; M Okada; T Takumi; M Nishita; Y Minami
Journal:  Oncogene       Date:  2009-06-29       Impact factor: 9.867

4.  Wnt5a signaling induces proliferation and survival of endothelial cells in vitro and expression of MMP-1 and Tie-2.

Authors:  T Néstor H Masckauchán; Dritan Agalliu; Marina Vorontchikhina; Audrey Ahn; Nancy L Parmalee; Chi-Ming Li; Alan Khoo; Benjamin Tycko; Anthony M C Brown; Jan Kitajewski
Journal:  Mol Biol Cell       Date:  2006-10-11       Impact factor: 4.138

5.  Runx2 recruits p300 to mediate parathyroid hormone's effects on histone acetylation and transcriptional activation of the matrix metalloproteinase-13 gene.

Authors:  Christine E Boumah; Minnkyong Lee; Nagarajan Selvamurugan; Emi Shimizu; Nicola C Partridge
Journal:  Mol Endocrinol       Date:  2009-05-07

6.  Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma.

Authors:  Kazuhito Morioka; Chizu Tanikawa; Kensuke Ochi; Yataro Daigo; Toyomasa Katagiri; Hirotaka Kawano; Hiroshi Kawaguchi; Akira Myoui; Hideki Yoshikawa; Norifumi Naka; Nobuto Araki; Ikuo Kudawara; Makoto Ieguchi; Kozo Nakamura; Yusuke Nakamura; Koichi Matsuda
Journal:  Cancer Sci       Date:  2009-04-15       Impact factor: 6.716

7.  Wnt 5a signaling is critical for macrophage-induced invasion of breast cancer cell lines.

Authors:  T Pukrop; F Klemm; Th Hagemann; D Gradl; M Schulz; S Siemes; L Trümper; C Binder
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-28       Impact factor: 11.205

8.  Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context.

Authors:  Amanda J Mikels; Roel Nusse
Journal:  PLoS Biol       Date:  2006-04-04       Impact factor: 8.029

9.  Filopodia formation mediated by receptor tyrosine kinase Ror2 is required for Wnt5a-induced cell migration.

Authors:  Michiru Nishita; Sa Kan Yoo; Akira Nomachi; Shuichi Kani; Nagako Sougawa; Yasutaka Ohta; Shinji Takada; Akira Kikuchi; Yasuhiro Minami
Journal:  J Cell Biol       Date:  2006-11-13       Impact factor: 10.539

10.  Ror2, a developmentally regulated kinase, promotes tumor growth potential in renal cell carcinoma.

Authors:  T M Wright; A R Brannon; J D Gordan; A J Mikels; C Mitchell; S Chen; I Espinosa; M van de Rijn; R Pruthi; E Wallen; L Edwards; R Nusse; W K Rathmell
Journal:  Oncogene       Date:  2009-05-18       Impact factor: 9.867

View more
  24 in total

Review 1.  The role of Ryk and Ror receptor tyrosine kinases in Wnt signal transduction.

Authors:  Jennifer Green; Roel Nusse; Renée van Amerongen
Journal:  Cold Spring Harb Perspect Biol       Date:  2014-02-01       Impact factor: 10.005

Review 2.  Small Rho GTPases in the control of cell shape and mobility.

Authors:  Arun Murali; Krishnaraj Rajalingam
Journal:  Cell Mol Life Sci       Date:  2013-11-26       Impact factor: 9.261

3.  Common polymorphism in the MMP-13 gene may contribute to the risk of human cancers: a meta-analysis.

Authors:  Ping Gao; Jun-Lan Yang; Hong Zhao; Jun-Hao You; Yi Hu
Journal:  Tumour Biol       Date:  2014-07-15

4.  Identification of Noncanonical Wnt Receptors Required for Wnt-3a-Induced Early Differentiation of Human Neural Stem Cells.

Authors:  Nora Bengoa-Vergniory; Irantzu Gorroño-Etxebarria; Inmaculada López-Sánchez; Michele Marra; Pierluigi Di Chiaro; Robert Kypta
Journal:  Mol Neurobiol       Date:  2016-10-05       Impact factor: 5.590

5.  Knockdown of receptor tyrosine kinase-like orphan receptor 2 inhibits cell proliferation and colony formation in osteosarcoma cells by inducing arrest in cell cycle progression.

Authors:  Jianjun Huang; Ying Shi; Hui Li; Dunyong Tan; Meisongzhu Yang; Xiang Wu
Journal:  Oncol Lett       Date:  2015-10-12       Impact factor: 2.967

6.  cRel and Wnt5a/Frizzled 5 Receptor-Mediated Inflammatory Regulation Reveal Novel Neuroprotectin D1 Targets for Neuroprotection.

Authors:  Jorgelina M Calandria; Khanh V Do; Sayantani Kala-Bhattacharjee; Andre Obenaus; Ludmila Belayev; Nicolas G Bazan
Journal:  Cell Mol Neurobiol       Date:  2022-05-27       Impact factor: 4.231

7.  Receptor tyrosine kinase-like orphan receptor 2 (Ror2) expression creates a poised state of Wnt signaling in renal cancer.

Authors:  Neal R Rasmussen; Tricia M Wright; Samira A Brooks; Kathryn E Hacker; Zufan Debebe; Adam B Sendor; Matthew P Walker; Michael Ben Major; Jennifer Green; Geoffrey M Wahl; W Kimryn Rathmell
Journal:  J Biol Chem       Date:  2013-07-26       Impact factor: 5.157

8.  ANKRD1 acts as a transcriptional repressor of MMP13 via the AP-1 site.

Authors:  Karinna Almodóvar-García; Minjae Kwon; Susan E Samaras; Jeffrey M Davidson
Journal:  Mol Cell Biol       Date:  2014-02-10       Impact factor: 4.272

9.  WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth.

Authors:  Craig S Thomson; Jay Pundavela; Melissa R Perrino; Robert A Coover; Kwangmin Choi; Katherine E Chaney; Tilat A Rizvi; David A Largaespada; Nancy Ratner
Journal:  Oncogene       Date:  2021-06-02       Impact factor: 9.867

10.  Wnt5a inhibits the proliferation and melanogenesis of melanocytes.

Authors:  Jie Zhang; Yan Li; Yun Wu; Tian Yang; Ke Yang; Ruimin Wang; Jin Yang; Haiying Guo
Journal:  Int J Med Sci       Date:  2013-04-05       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.